m+Medelevator.RU
← Поиск публикаций
Journal of clinical medicine · 2026

Machine Learning Models for Predicting Bleeding Risk in Anticoagulated Patients with Atrial Fibrillation and Venous Thromboembolism: A Comparative Evidence Synthesis.

СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Teo Winnie Z Y, Wong Maggie Wing Yin, Lim Fang Jin, Ong Emmeliene Su-Min, Barr Kumarakulasinghe Nesaretnam, Yap Eng Soo

Аннотация

Background: Accurate prediction of bleeding events in patients receiving oral anticoagulants remains a key challenge in the management of atrial fibrillation (AF) and venous thromboembolism (VTE). Machine learning (ML) algorithms have emerged as powerful tools that capture complex, nonlinear interactions among risk factors, potentially offering superior accuracy. Objectives: To synthesize evidence comparing ML-based bleeding risk models with conventional clinical scores in anticoagulated AF and VTE populations. Methods: We conducted a systematic review with narrative synthesis of studies published between 2015 and 2025 applying ML algorithms to predict bleeding events in anticoagulated AF or VTE patients. Results: Thirteen studies were identified (seven AF and six VTE), including 464,523 participants in total. ML algorithms such as random forest (RF), extreme gradient boosting (XGBoost), and neural networks consistently outperformed traditional tools. In AF, AUCs ranged from 0.64 to 0.76 compared to 0.52-0.61 for HAS-BLED. In VTE, ML models achieved 0.59-0.91 versus 0.61-0.65 for RIETE or VTE-BLEED. Deep learning ensembles reached the highest AUCs (>0.8). Conclusions: ML-based bleeding risk models demonstrated statistically superior discrimination compared to established scores in both AF and VTE contexts, but effect sizes were modest (ΔAUC 0.05-0.15) and clinical utility remains uncertain. Broader validation, calibration assessment, and demonstration of impact on clinical outcomes are necessary before routine adoption.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты